To view this email as a web page, click here.

Ribociclib Addition May Benefit Women With Advanced HR-Positive Breast Cancer

The MONALEESA-7 trial tested the combination of ribociclib with endocrine therapy in premenopausal women with advanced HR-positive/HER2-negative breast cancer.

Using Genomic Profiling to Guide Treatment Decisions for ER-Positive Breast Cancers

We discuss the use of genomic profiling to guide treatment decisions for ER+ breast cancer patients with Harold J. Burstein, MD, PhD, who is presenting at the ASCO Annual Meeting today.

Pembrolizumab May Be an Alternative to Chemo for Select Patients With Gastric Cancers

Select patients with advanced gastric or gastroesophageal junction cancer may benefit from initial therapy with pembrolizumab, according to the KEYNOTE-062 trial.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.